The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat

被引:49
|
作者
Kinoshita, T
Miyake, H
Fujii, T
Takakura, S
Goto, T
机构
[1] Fujisawa Pharmaceut Co Ltd, Exploratory Res Labs, Tsukuba, Ibaraki 3002698, Japan
[2] Fujisawa Pharmaceut Co Ltd, Med Biol Res Labs, Yodogawa Ku, Osaka 5328514, Japan
关键词
D O I
10.1107/S0907444902002378
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The crystal structure of the complex of human recombinant aldose reductase (AR) with zenarestat, one of its potent inhibitors, has been solved at 2.5 Angstrom resolution. Zenarestat fits neatly in the hydrophobic active site and induces unique and dramatic conformational changes. For example, the benzene ring of zenarestat occupies a gap in the side chains of Leu300 and Trp111 that interact directly and forms a CH-pi interaction in the native holoenzyme. As a result, the benzene ring of the inhibitor and these side chains form a CH-pi-pi interaction. Such structural information is key to understanding the mode of action of this class of inhibitors and for rational design of better therapeutics.
引用
收藏
页码:622 / 626
页数:5
相关论文
共 50 条
  • [31] EFFECT OF A NEW POTENT ALDOSE REDUCTASE INHIBITOR, TAT ON DIABETIC NEUROPATHY OF RATS
    HOTTA, N
    KAKUTA, H
    KOH, N
    SAKAKIBARA, F
    KOMORI, H
    INUKAI, S
    NAITO, S
    SAKAMOTO, N
    DIABETOLOGIA, 1992, 35 : A151 - A151
  • [32] ANTIOXIDANT ACTIVITY IN VIVO OF A POTENT AND MULTIFUNCTIONAL ALDOSE REDUCTASE INHIBITOR BASED ON QUINOXALINONE
    Xiangyu, Q.
    Changjin, Z.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 117 : 2 - 3
  • [33] Topical aldose reductase inhibitor
    Coster, D
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (12) : 1064 - 1065
  • [34] THE ALDOSE REDUCTASE INHIBITOR SITE
    KADOR, PF
    KINOSHITA, JH
    SHARPLESS, NE
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1986, 35 (04): : 109 - 113
  • [35] Inhibitory effect of ursolic acid derivatives on recombinant human aldose reductase
    Lee, Eun Ha
    Popov, S. A.
    Lee, Joo Young
    Shpatov, A. V.
    Kukina, T. P.
    Kang, Suk Woo
    Pan, Cheol Ho
    Um, Byung Hun
    Jung, Sang Hoon
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2011, 37 (05) : 569 - 577
  • [36] Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats
    Ashizawa, N
    Yoshida, M
    Sugiyama, Y
    Akaike, N
    Ohbayashi, S
    Aotsuka, T
    Abe, N
    Fukushima, K
    Matsuura, A
    JAPANESE JOURNAL OF PHARMACOLOGY, 1997, 73 (02): : 133 - 144
  • [37] Addressing the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy, a Potent and Selective Next Generation Aldose Reductase Inhibitor
    Perfetti, Riccardo
    Yepuri, Gautham
    Quadri, Nosirudeen A.
    Ghannam, Ameen F.
    Ramasamy, Ravichandran
    Shendelman, Shoshana
    DIABETES, 2020, 69
  • [38] PURIFICATION AND CHARACTERIZATION OF THE RECOMBINANT HUMAN ALDOSE REDUCTASE EXPRESSED IN BACULOVIRUS SYSTEM
    NISHIMURA, C
    YAMAOKA, T
    MIZUTANI, M
    YAMASHITA, K
    AKERA, T
    TANIMOTO, T
    BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1078 (02) : 171 - 178
  • [39] Inhibitory effect of ursolic acid derivatives on recombinant human aldose reductase
    Eun Ha Lee
    S. A. Popov
    Joo Young Lee
    A. V. Shpatov
    T. P. Kukina
    Suk Woo Kang
    Cheol-Ho Pan
    Byung Hun Um
    Sang Hoon Jung
    Russian Journal of Bioorganic Chemistry, 2011, 37 : 569 - 577
  • [40] STRUCTURE-FUNCTION STUDIES OF HUMAN ALDOSE REDUCTASE
    CARPER, DA
    OLD, SE
    ELKABBANI, O
    HOHMAN, TC
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1995, 36 (04) : S821 - S821